|
| 37421603 | Natural history, predictors of development of extramedullary disease, and treatment outcomes for patients with extramedullary multiple myeloma. | | 2023 |
| 36226510 | Risk factors for severe infection and mortality In patients with COVID-19 in patients with multiple myeloma and AL amyloidosis. | American Journal of Hematology | 2023 |
| 36082445 | A pleiotropic variant in DNAJB4 is associated with multiple myeloma risk. | Int J Cancer | 2023 |
| 35413102 | Outcomes after biochemical or clinical progression in patients with multiple myeloma. | Blood advances | 2023 |
| 36413412 | Sarcopenia identified by computed tomography imaging using a deep learning-based segmentation approach impacts survival in patients with newly diagnosed multiple myeloma. | Cancer | 2023 |
| 38043989 | Discarded Treatments: When the Problem and the Solution Are More Than Meets the Eye. | | 2023 |
| 37603349 | Outcomes of patients with primary refractory multiple myeloma in the era of triplet and quadruplet induction therapy. | | 2023 |
| 38024593 | Late versus early response and depth of response are associated with improved outcomes in patients with newly diagnosed multiple myeloma enrolled in the TOURMALINE-MM2 trial. | | 2023 |
| 37926718 | Once-weekly bortezomib as the standard of care in multiple myeloma: results from an international survey of physicians. | | 2023 |
| 37659912 | Current approach to Waldenström macroglobulinemia. | | 2023 |
| 37658775 | Superior detection rate of plasma cell FISH using FACS-FISH. | | 2023 |
| 37723249 | Identification of novel genetic loci for risk of multiple myeloma by functional annotation. | Leukemia | 2023 |
| 38086801 | Muscle and fat composition in patients with newly diagnosed multiple myeloma. | | 2023 |
| 38072941 | Comparison of daratumumab-based regimens as second-line therapy in relapsed/refractory multiple myeloma. | | 2023 |
| 37961238 | Mode of Progression in Smoldering Multiple Myeloma: A study of 406 patients. | | 2023 |
| 37414019 | Management of multiple myeloma-related renal impairment: recommendations from the International Myeloma Working Group. | | 2023 |
| 36588396 | Thrombosis in multiple myeloma: Risk estimation by induction regimen and association with overall survival. | | 2023 |
| 36588384 | Survival trends in young patients with Waldenström macroglobulinemia: Over five decades of experience. | | 2023 |
| 37468552 | Correction: "The 5th edition of The World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms" Leukemia. 2022 Jul;36(7):1720-1748. | Leukemia | 2023 |
| 37149398 | Ixazomib Versus Placebo as Postinduction Maintenance Therapy in Newly Diagnosed Multiple Myeloma Patients: An Analysis by Age and Frailty Status of the TOURMALINE-MM4 Study. | | 2023 |
| 37334773 | A phase 1/2 of carfilzomib and melphalan conditioning for autologous stem cell transplantation for multiple myeloma (CARAMEL). | | 2023 |
| 37147423 | Relationship among three common hematological premalignant conditions. | Leukemia | 2023 |
| 37080968 | Utility of flow cytometry screening before MRD testing in multiple myeloma. | | 2023 |
| 37263762 | Defining Myeloma and Advancing Treatment Options: A Conversation Between S. Vincent Rajkumar and Lale Kostakoglu. | | 2023 |
| 36631458 | A pooled analysis of outcomes according to cytogenetic abnormalities in patients receiving ixazomib- vs placebo-based therapy for multiple myeloma. | | 2023 |
| 36631454 | Defining drug/drug class refractoriness vs lines of therapy in relapsed/refractory multiple myeloma. | | 2023 |
| 36482129 | Value of bone marrow examination in determining response to therapy in patients with multiple myeloma in the context of mass spectrometry-based M-protein assessment. | | 2023 |
| 37253713 | Daratumumab, carfilzomib, and pomalidomide for the treatment of POEMS syndrome: The Mayo Clinic Experience. | | 2023 |
| 37188699 | Conditional survival in multiple myeloma and impact of prognostic factors over time. | Blood Cancer J | 2023 |
| 37002539 | The nephrotoxicity of bortezomib: did we miss a complication after 20 years of use and multiple landmark trials? | | 2023 |
| 36797276 | Artificial intelligence-enabled screening strategy for drug repurposing in monoclonal gammopathy of undetermined significance. | Blood Cancer J | 2023 |
| 37232112 | Kappa Free Light Chain Drift Prompts the Need for a New Upper Limit of Normal Free Light Chain Ratio to Avoid an Epidemic of Kappa Light Chain Monoclonal Gammopathy of Undermined Significance. | J Appl Lab Med | 2023 |
| 36990996 | Multiple myeloma with acute light chain cast nephropathy. | | 2023 |
| 36533960 | The impact of Post-Transplant doxycycline in AL amyloidosis - updated results after Long-Term follow up. | | 2023 |
| 37494698 | Impact of cytogenetic abnormalities on the risk of disease progression in solitary bone plasmacytomas. | | 2023 |
| 34635783 | Outcomes of triple class (proteasome inhibitor, IMiDs and monoclonal antibody) refractory patients with multiple myeloma. | Leukemia | 2022 |
| 35580285 | Patient Experience in Clinical Trials: Quality of Life, Financial Burden, and Perception of Care in Patients With Multiple Myeloma or Lymphoma Enrolled on Clinical Trials Compared With Standard Care. | JCO Oncol Pract | 2022 |
| 36096078 | Risk factors for severe infection and mortality in COVID-19 and monoclonal gammopathy of undetermined significance. | Blood | 2022 |
| 35700034 | Does a Multiple Myeloma Polygenic Risk Score Predict Overall Survival of Patients with Myeloma? | Cancer Epidemiol Biomarkers Prev | 2022 |
| 35646666 | Single-Cell Proteomics and Tumor RNAseq Identify Novel Pathways Associated With Clofazimine Sensitivity in PI- and IMiD- Resistant Myeloma, and Putative Stem-Like Cells. | Front Oncol | 2022 |
| 35440099 | Body mass index associated with monoclonal gammopathy of undetermined significance (MGUS) progression in Olmsted County, Minnesota. | Blood Cancer Journal | 2022 |
| 35882836 | Distribution of clonal hematopoiesis of indeterminate potential (CHIP) is not associated with race in patients with plasma cell neoplasms. | Blood Cancer J | 2022 |
| 35694818 | Impact of belantamab mafodotin-induced ocular toxicity on outcomes of patients with advanced multiple myeloma. | British Journal of Haematology | 2022 |
| 36213348 | Cardiovascular Associations With Monoclonal Gammopathy of Undetermined Significance: Real or Coincidental? | JACC: CardioOncology | 2022 |
| 35497786 | Kidney Transplant Outcomes of Patients With Multiple Myeloma. | Kidney International Reports | 2022 |
| 35940527 | Deepening Responses after Upfront Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma in the Era of Novel Agent Induction Therapy. | Transplantation and Cellular Therapy | 2022 |
| 35560063 | Multiple myeloma: 2022 update on diagnosis, risk stratification, and management. | American Journal of Hematology | 2022 |
| 35800433 | Hypovitaminosis D Is Prevalent in Patients With Renal AL Amyloidosis and Associated With Renal Outcome. | Frontiers in Endocrinology | 2022 |
| 35737873 | Phase 2 trial of ixazomib, cyclophosphamide, and dexamethasone for previously untreated light chain amyloidosis. | Blood advances | 2022 |
| 36333013 | Failure to Launch: Why Some Generics Don't Take. | Mayo Clinic Proceedings | 2022 |